Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to share pricing for the Performance Share Plan:
- Ordinary Share price: 1,420 pence
- American Depositary Share (ADS) price: $45.47
Material Changes
The filing details an increase in notional interests in Ordinary Shares and ADSs for various executives following the notional re-investment of the dividend paid to shareholders on April 12, 2012. No comparative financial changes versus prior periods are reported in this document.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly reports on the administrative update of the Performance Share Plan, noting that accrued notional dividends will be paid out based on vesting percentages after the relevant three-year measurement period.
Investor Verification Points
- Verify the specific number of Ordinary Shares and ADSs allocated to each named executive in the Performance Share Plan.
- Confirm the dividend payment date of April 12, 2012, and the associated re-investment price.
- Note that this filing does not contain operational or financial results; refer to Form 20-F or quarterly earnings releases for financial performance.